Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | GFER | P55789 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19757397 | 0.88 | KDM4E (0.45) | KDM4ERAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL2740239 | 0.85 | SIRT1 (0.56) | KDM4ERAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL18993820 | 0.84 | SMO (0.49) | KDM4ERAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL2624739 | 0.80 | KDM4E (0.55) | KDM4ERAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL2740428 | 0.79 | TP53 (0.52) | KDM4ERAB9APOLBSIRT1ALDH1A1 | |
| SCHEMBL25878632 | 0.79 | KDM4E (0.74) | KDM4ERAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL2624740 | 0.78 | KDM4E (0.62) | KDM4ERAB9ALMNAPOLBSIRT1 | |
| SCHEMBL2624506 | 0.72 | TLR9 (0.63) | KDM4ERAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL12422026 | 0.72 | KDM4E (0.74) | KDM4ERAB9ASMN1; SMN2LMNAPOLB | |
| SCHEMBL2740161 | 0.72 | SIRT1 (0.56) | KDM4ERAB9ASIRT1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10383837-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-20190224152-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2019-07-25 | — | — | US | disclosed |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2017-11-02 | — | — | US | disclosed |
| US-9682053-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682053-B2 | Compositions and methods for modulating metabolic pathways | NUSIRT SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585907-B2 | Methods and compositions for modulating Tau levels | THE J. DAVID GLADSTONE INSTITUTES (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160338983-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20160338983-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | NUMETA SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRTIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| WO-2007019345-A1 | IMIDAZOPYRIDINE DERIVATIVES AS SIRTUIN MODULATING AGENTS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037827-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRT2, SIRT1, SIRT3 | KDM4E 1227/4885RAB9A 515/4885SMN1; SMN2 1160/4885 |
| US-20190224152-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | KDM4E 777/4885RAB9A 3485/4885SMN1; SMN2 2688/4885 |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | KDM4E 540/4885RAB9A 1526/4885SMN1; SMN2 2663/4885 |
| US-20070037865-A1 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; benzimidazo drivatives | SIRT2, SIRT1, SIRT3 | KDM4E 1399/4885RAB9A 589/4885SMN1; SMN2 1245/4885 |
| US-20170312240-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | KDM4E 777/4885RAB9A 3485/4885SMN1; SMN2 2688/4885 |
| US-20070043050-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | KDM4E 1388/4885RAB9A 1397/4885SMN1; SMN2 2106/4885 |
| US-10383837-B2 | Compositions and methods for modulating metabolic pathways | PC, HADHB, ACACB | KDM4E 777/4885RAB9A 3485/4885SMN1; SMN2 2688/4885 |
| US-20160338983-A1 | COMPOSITIONS AND METHODS FOR MODULATING METABOLIC PATHWAYS | PC, HADHB, ACACB | KDM4E 777/4885RAB9A 3485/4885SMN1; SMN2 2688/4885 |
| US-20070037810-A1 | Sirtuin modulating compounds | SIRT1, SIRT3, SIRT2 | KDM4E 1388/4885RAB9A 1397/4885SMN1; SMN2 2106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.